Clearwater: Phone: 727.977.9717 I Fax: 727.977.9717
Tampa: Phone: 813.775.9997 I Fax: 813.775.9997
Email: intake@sageinfusion.com I Online: www.sageinfusion.com

Tysabri (Natalizumab) Infusion Orders

Patient Name: DOB: ☐ Male ☐ Female

Diagnosis (please provide ICD10 code)

☐ NKDA Allergies:

☐ New Start Therapy ☐ Continuation of Therapy Date of last dose (if applicable):

Ordering Provider:

Provider NPI: Phone: Fax:

Practice Address: City: State: Zip Code:

PREMEDICATION

☐ Acetaminophen1000mg PO
☐ Diphenhydramine 25mg PO
☐ Ceterizine 10mg PO
☐ Solu-Medrol 125mg IVP Solu-
☐ Cortef 100mg IVP
☐ Diphenhydramine 25mg IVP

REQUIRED DOCUMENTS

☑ Clinical/Progress Notes, Labs, Tests supporting primary diagnosis (please attach)
☑ Most Recent Labs including anti-JCV antibodies
☑ Tysabri TOUCH Authorization Form
☑ Previous MS Drug Therapy History, including therapies trailed and or failed

TYSABRI ORDERS

DOSING:

☑ 300mg in 100ml 0.9% sodium chloride, intravenous infusion, administered over 60 minutes

FREQUENCY:

☑ Every 4 weeks (28 days)

Other: _____

REFILLS:

☐ _____
(if not indicated prescription will expire one year from date signed)

Sage Infusion Standing Orders:

☑ Provide treatment under Sage Infusion's Clinical Guidelines, Medication Safety Protocol, Emergency Guidelines, and Action Plan for Infusion Reactions.

_____

Provider Name

_____ _____

Provider Signature Date

Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability. Risk factors for the development of PML include the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants. These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri. Monitor patients, and withhold Tysabri immediately at the first sign or symptom suggestive of PML. Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program.